

"Ashes to Ashes"

The phrase “ashes to ashes, dust to dust” is derived from the Biblical text of *Genesis 3:19* and was adapted to its present form at an old English burial service. Last week I repeated those words as I scattered my father’s ashes next to my mother’s in the memorial garden of the church they loved so much in Richmond, Virginia. Indeed, my week was spent in Richmond, Washington D.C., and Baltimore seeing institutional accounts, consulting with political types, and speaking at various events for our financial advisors and their clients. Other than my dad’s service, the highlight of the week was D.C. because of the drama currently playing inside the Beltway. I think the “budget” charade ends this coming weekend for the reasons stated in last Monday’s missive. To wit, politics is all about political interests and survival. To that point, the President is not up for election ever again, the Senators and Congress folks are. It’s pretty easy to figure out who wins that game of chicken. Moreover, the budget deficit is collapsing at a much faster rate than even the non-partisan CBO suggested. That reduces support for tax increases and spending cuts. More importantly, the Republicans have ceased bargaining their budgetary votes away in exchange for tax and spending cuts. Their “cry” now is to repeal/defund Obamacare, which I have repeatedly stated is a flawed strategy. While one can argue it is the principal of the thing, in the real world Obamacare is here to stay, although it could be tweaked to be more practical. As one governmental insider told me (as paraphrased):

The proof of whether Obamacare is going to work will be seen over the next three months. How many uninsured will sign up? My guess is that half, at the most, will sign up even though the legislation was clearly designed to benefit them with federal subsidies to make insurance affordable for them. I will bet three-fourths of the uninsured don't even understand the details. What will the Obamacare advocates say when only one third of the uninsured sign up? The goal was to make available health insurance for all Americans, but what happens when the uninsured don't play ball? Even young, healthy Americans might defer buying insurance because they are in a mental-complacency rut and have other interests for the way they spend their money. We could learn from other societies; Singapore, which is one of the most dynamic business communities in the world, requires all workers to have their own personal health care fund, and each person must contribute to it each month. QED . . .

This week I will be in Boca Raton speaking at a national conference and seeing accounts, followed by a speaking tour in Michigan. Interestingly, individual investors want to know what the professional money managers I have been seeing are doing, while the money managers want to know what individual investors are doing. In regards to the latter question, individual investors seem to be “frozen” like deer in the headlights, believing that you need to have a feel good environment to have a secular bull market. The reality of the matter is that when you finally get that “feel good” environment, it tends to be pretty late in the overall scheme of things. To be sure, it was very easy to buy tech stocks in 1999, but that proved to be a flawed strategy. Over the past few years it has been pretty easy to buy “bonds,” but that too has proven to be a flawed strategy since the bond bull market appears to have ended. Manifestly, I think you should be very careful with the fixed income allocation of your portfolio at this point. Indeed, since July of last year interest rates have doubled, with a concurrent decline in most bond funds. As a sidebar, bond funds are not fixed income since bond funds have no maturity date. If you disagree, just look at how most bond funds have performed over the last few months. The exception has been the only bond fund that I currently own, and have recommended numerous times in these missives, namely the Putnam Diversified Income Trust (PDINX/\$7.78). I still advise you to consider PDINX for the fixed income allocation of your portfolio.

As for the equity markets, I think the budgetary charade ends this coming weekend. To me, the only question is if we get a post-weekend stock market “let down,” since Friday’s Fling (+76.10 points) seemed to be all about hopes for a budgetary agreement over the weekend. Interestingly, while the D-J Industrial Average (INDU/15072.58) and the S&P 500 (SPX/1690.50) were both lower last week, the small and mid-cap indices were virtually unchanged. Indeed, of all the indices I monitor only those two, and the D-J Utility Index, were down for the week. This suggests the equity markets’ primary trend remains “up.” This view is also confirmed by the Advance/Decline figures, as well as the Buying Power/Selling Pressure indicators. Surprisingly, the NASDAQ Computer Index, and the NASDAQ Financial Index, resisted the decline of the past week, which potentially means those two sectors could assume more leadership when the overall stock market regains its footing. To the relative strength point, the S&P 400 MidCap Index and the S&P 600 SmallCap made new bull market highs last week, which is certainly good for Raymond James’ universe of research names. As for the S&P 500’s 10 macro sectors, only

[Please read domestic and foreign disclosure/risk information beginning on page 4 and Analyst Certification on page 4.](#)


Consumer Discretionary (+0.21%), Healthcare (+0.94%), and Materials (+0.84) were positive for the week. I find that sector performance insightful because two of those sectors are economically sensitive, implying the economy should strengthen into 2014.

As for the negative article in last Friday's *Wall Street Journal* titled, "Companies Rush to Lower Earnings Bar," which so many clients have emailed me about, I would not put much emphasis on the cautionary tone U.S. companies are sounding about third quarter earnings. The article notes that there have been 89 negative preannouncements so far and only 19 positive ones for the S&P 500 companies. The *Journal* says, "That makes for a record-high ratio of 4.7 times." The article continues by stating:

"The ratio was even more skewed last quarter for the 111 companies that bothered to issue some type of explicit guidance, according to FactSet. Of those, 86% exceeded the number or range they had given themselves, while only 9% lagged behind. . . . [Therefore] negative guidance on its own probably isn't a worry for the market overall."

Not a worry indeed, because history shows such guidance is more of a contrary indicator. While it is not exactly the data set the *Journal* used, the chart on page 3 demonstrates the validity of this data set as a contrary indicator.

The call for this week: I think the budget conflagration turns into "ashes to ashes, dust to dust" by this time next week, allowing the equity markets to refocus on some of the good things that are occurring. Last week the SPX rallied back toward its overhead resistance at 1695 – 1710 and stalled with Friday's lift, caused by hopes for a budgetary deal over the weekend. With no deal, we should see another pullback toward my often mentioned 1684 "pivot point;" and, isn't it amazing how that level has acted as an attractor/repeller so many times. This morning our leaders remain intransigent on a budgetary compromise. That news, along with the World Bank's lowering of the expected growth rate for China, has the reopening SPX futures off 16 points. As I wrote in last week's Morning Tack, "1684 or fight!"



Source: sentimenTrader.com.



Modest improvement in the latest week, but still negative right at downtrend.

Source: Bespoke Investment Group.

Important Investor Disclosures

Raymond James & Associates (RJA) is a FINRA member firm and is responsible for the preparation and distribution of research created in the United States. Raymond James & Associates is located at The Raymond James Financial Center, 880 Carillon Parkway, St. Petersburg, FL 33716, (727) 567-1000. Non-U.S. affiliates, which are not FINRA member firms, include the following entities which are responsible for the creation and distribution of research in their respective areas; In Canada, Raymond James Ltd. (RJL), Suite 2100, 925 West Georgia Street, Vancouver, BC V6C 3L2, (604) 659-8200; In Latin America, Raymond James Latin America (RJLatAm), Ruta 8, km 17, 500, 91600 Montevideo, Uruguay, 00598 2 518 2033; In Europe, Raymond James Euro Equities, SAS (RJEE), 40, rue La Boetie, 75008, Paris, France, +33 1 45 61 64 90.

This document is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of or located in any locality, state, country, or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. The securities discussed in this document may not be eligible for sale in some jurisdictions. This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. **Investors should consider this report as only a single factor in making their investment decision.**

For clients in the United States: Any foreign securities discussed in this report are generally not eligible for sale in the U.S. unless they are listed on a U.S. exchange. This report is being provided to you for informational purposes only and does not represent a solicitation for the purchase or sale of a security in any state where such a solicitation would be illegal. Investing in securities of issuers organized outside of the U.S., including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of, the U.S. Securities and Exchange Commission. There may be limited information available on such securities. Investors who have received this report may be prohibited in certain states or other jurisdictions from purchasing the securities mentioned in this report. Please ask your Financial Advisor for additional details and to determine if a particular security is eligible for solicitation in your state.

The information provided is as of the date above and subject to change, and it should not be deemed a recommendation to buy or sell any security. Certain information has been obtained from third-party sources we consider reliable, but we do not guarantee that such information is accurate or complete. Persons within the Raymond James family of companies may have information that is not available to the contributors of the information contained in this publication. Raymond James, including affiliates and employees, may execute transactions in the securities listed in this publication that may not be consistent with the ratings appearing in this publication.

Additional information is available on request.

Analyst Information

Registration of Non-U.S. Analysts: The analysts listed on the front of this report who are not employees of Raymond James & Associates, Inc., are not registered/qualified as research analysts under FINRA rules, are not associated persons of Raymond James & Associates, Inc., and are not subject to NASD Rule 2711 and NYSE Rule 472 restrictions on communications with covered companies, public companies, and trading securities held by a research analyst account.

Analyst Holdings and Compensation: Equity analysts and their staffs at Raymond James are compensated based on a salary and bonus system. Several factors enter into the bonus determination including quality and performance of research product, the analyst's success in rating stocks versus an industry index, and support effectiveness to trading and the retail and institutional sales forces. Other factors may include but are not limited to: overall ratings from internal (other than investment banking) or external parties and the general productivity and revenue generated in covered stocks.

The views expressed in this report accurately reflect the personal views of the analyst(s) covering the subject securities. No part of said person's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in this research report. In addition, said analyst has not received compensation from any subject company in the last 12 months.

Ratings and Definitions

Raymond James & Associates (U.S.) definitions

Strong Buy (SB1) Expected to appreciate, produce a total return of at least 15%, and outperform the S&P 500 over the next six to 12 months. For higher yielding and more conservative equities, such as REITs and certain MLPs, a total return of at least 15% is expected to be realized over the next 12 months.

Outperform (MO2) Expected to appreciate and outperform the S&P 500 over the next 12-18 months. For higher yielding and more conservative equities, such as REITs and certain MLPs, an Outperform rating is used for securities where we are comfortable with the relative safety of the dividend and expect a total return modestly exceeding the dividend yield over the next 12-18 months.

Market Perform (MP3) Expected to perform generally in line with the S&P 500 over the next 12 months.

Underperform (MU4) Expected to underperform the S&P 500 or its sector over the next six to 12 months and should be sold.

Suspended (S) The rating and price target have been suspended temporarily. This action may be due to market events that made coverage impracticable, or to comply with applicable regulations or firm policies in certain circumstances, including when Raymond James may be providing investment banking services to the company. The previous rating and price target are no longer in effect for this security and should not be relied upon.

Raymond James Ltd. (Canada) definitions

Strong Buy (SB1) The stock is expected to appreciate and produce a total return of at least 15% and outperform the S&P/TSX Composite Index over the next six months.

Outperform (MO2) The stock is expected to appreciate and outperform the S&P/TSX Composite Index over the next twelve months.

Market Perform (MP3) The stock is expected to perform generally in line with the S&P/TSX Composite Index over the next twelve months and is potentially a source of funds for more highly rated securities.

Underperform (MU4) The stock is expected to underperform the S&P/TSX Composite Index or its sector over the next six to twelve months and should be sold.

Raymond James Latin American rating definitions

Strong Buy (SB1) Expected to appreciate and produce a total return of at least 25.0% over the next twelve months.

Outperform (MO2) Expected to appreciate and produce a total return of between 15.0% and 25.0% over the next twelve months.

Market Perform (MP3) Expected to perform in line with the underlying country index.

Underperform (MU4) Expected to underperform the underlying country index.

Suspended (S) The rating and price target have been suspended temporarily. This action may be due to market events that made coverage impracticable, or to comply with applicable regulations or firm policies in certain circumstances, including when Raymond James may be providing investment banking services to the company. The previous rating and price target are no longer in effect for this security and should not be relied upon.

Raymond James Euro Equities, SAS rating definitions

Strong Buy (1) Expected to appreciate, produce a total return of at least 15%, and outperform the Stoxx 600 over the next 6 to 12 months.

Outperform (2) Expected to appreciate and outperform the Stoxx 600 over the next 12 months.

Market Perform (3) Expected to perform generally in line with the Stoxx 600 over the next 12 months.

Underperform (4) Expected to underperform the Stoxx 600 or its sector over the next 6 to 12 months.

Suspended (S) The rating and target price have been suspended temporarily. This action may be due to market events that made coverage impracticable, or to comply with applicable regulations or firm policies in certain circumstances, including when Raymond James may be providing investment banking services to the company. The previous rating and target price are no longer in effect for this security and should not be relied upon.

In transacting in any security, investors should be aware that other securities in the Raymond James research coverage universe might carry a higher or lower rating. Investors should feel free to contact their Financial Advisor to discuss the merits of other available investments.

Rating Distributions

	Coverage Universe Rating Distribution				Investment Banking Distribution			
	RJA	RJL	RJ LatAm	RJEE	RJA	RJL	RJ LatAm	RJEE
Strong Buy and Outperform (Buy)	51%	60%	43%	48%	24%	31%	0%	0%
Market Perform (Hold)	43%	39%	57%	31%	9%	23%	0%	0%
Underperform (Sell)	6%	1%	0%	21%	3%	0%	0%	0%

Suitability Categories (SR)

Total Return (TR) Lower risk equities possessing dividend yields above that of the S&P 500 and greater stability of principal.

Growth (G) Low to average risk equities with sound financials, more consistent earnings growth, at least a small dividend, and the potential for long-term price appreciation.

Aggressive Growth (AG) Medium or higher risk equities of companies in fast growing and competitive industries, with less predictable earnings and acceptable, but possibly more leveraged balance sheets.

High Risk (HR) Companies with less predictable earnings (or losses), rapidly changing market dynamics, financial and competitive issues, higher price volatility (beta), and risk of principal.

Venture Risk (VR) Companies with a short or unprofitable operating history, limited or less predictable revenues, very high risk associated with success, and a substantial risk of principal.

Raymond James Relationship Disclosures

Raymond James expects to receive or intends to seek compensation for investment banking services from the subject companies in the next three months.

Stock Charts, Target Prices, and Valuation Methodologies

Valuation Methodology: The Raymond James methodology for assigning ratings and target prices includes a number of qualitative and quantitative factors including an assessment of industry size, structure, business trends and overall attractiveness; management effectiveness; competition; visibility; financial condition, and expected total return, among other factors. These factors are subject to change depending on overall economic conditions or industry- or company-specific occurrences. Only stocks rated Strong Buy (SB1) or Outperform (MO2) have target prices and thus valuation methodologies.

Target Prices: The information below indicates target price and rating changes for the subject companies included in this research.

Risk Factors

General Risk Factors: Following are some general risk factors that pertain to the projected target prices included on Raymond James research: (1) Industry fundamentals with respect to customer demand or product / service pricing could change and adversely impact expected revenues and earnings; (2) Issues relating to major competitors or market shares or new product expectations could change investor attitudes toward the sector or this stock; (3) Unforeseen developments with respect to the management, financial condition or accounting policies or practices could alter the prospective valuation; or (4) External factors that affect the U.S. economy, interest rates, the U.S. dollar or major segments of the economy could alter investor confidence and investment prospects. International investments involve additional risks such as currency fluctuations, differing financial accounting standards, and possible political and economic instability.

Additional Risk and Disclosure information, as well as more information on the Raymond James rating system and suitability categories, is available at rjcapitalmarkets.com/Disclosures/index. Copies of research or Raymond James' summary policies relating to research analyst independence can be obtained by contacting any Raymond James & Associates or Raymond James Financial Services office (please see raymondjames.com for office locations) or by calling 727-567-1000, toll free 800-237-5643 or sending a written request to the Equity Research Library, Raymond James & Associates, Inc., Tower 3, 6th Floor, 880 Carillon Parkway, St. Petersburg, FL 33716.

International securities involve additional risks such as currency fluctuations, differing financial accounting standards, and possible political and economic instability. These risks are greater in emerging markets.

Small-cap stocks generally involve greater risks. Dividends are not guaranteed and will fluctuate. Past performance may not be indicative of future results.

Investors should consider the investment objectives, risks, and charges and expenses of mutual funds carefully before investing. The prospectus contains this and other information about mutual funds. The prospectus is available from your financial advisor and should be read carefully before investing.

For clients in the United Kingdom:

For clients of Raymond James & Associates (London Branch) and Raymond James Financial International Limited (RJFI): This document and any investment to which this document relates is intended for the sole use of the persons to whom it is addressed, being persons who are Eligible Counterparties or Professional Clients as described in the FCA rules or persons described in Articles 19(5) (Investment professionals) or 49(2) (High net worth companies, unincorporated associations etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or any other person to whom this promotion may lawfully be directed. It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons and may not be relied upon by such persons and is therefore not intended for private individuals or those who would be classified as Retail Clients.

For clients of Raymond James Investment Services, Ltd.: This report is for the use of professional investment advisers and managers and is not intended for use by clients.

For purposes of the Financial Conduct Authority requirements, this research report is classified as independent with respect to conflict of interest management. RJA, RJFI, and Raymond James Investment Services, Ltd. are authorised and regulated by the Financial Conduct Authority in the United Kingdom.

For clients in France:

This document and any investment to which this document relates is intended for the sole use of the persons to whom it is addressed, being persons who are Eligible Counterparties or Professional Clients as described in “Code Monétaire et Financier” and Règlement Général de l’Autorité des Marchés Financiers. It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons and may not be relied upon by such persons and is therefore not intended for private individuals or those who would be classified as Retail Clients.

For institutional clients in the European Economic Area (EEA) outside of the United Kingdom:

This document (and any attachments or exhibits hereto) is intended only for EEA institutional clients or others to whom it may lawfully be submitted.

Raymond James International and Raymond James Euro Equities are authorized by the Autorité de Contrôle Prudentiel in France and regulated by the Autorité de Contrôle Prudentiel and the Autorité des Marchés Financiers.

For Canadian clients:

This report is not prepared subject to Canadian disclosure requirements, unless a Canadian analyst has contributed to the content of the report. In the case where there is Canadian analyst contribution, the report meets all applicable IROC disclosure requirements.

Proprietary Rights Notice: By accepting a copy of this report, you acknowledge and agree as follows:

This report is provided to clients of Raymond James only for your personal, noncommercial use. Except as expressly authorized by Raymond James, you may not copy, reproduce, transmit, sell, display, distribute, publish, broadcast, circulate, modify, disseminate or commercially exploit the information contained in this report, in printed, electronic or any other form, in any manner, without the prior express written consent of Raymond James. You also agree not to use the information provided in this report for any unlawful purpose.

This report and its contents are the property of Raymond James and are protected by applicable copyright, trade secret or other intellectual property laws (of the United States and other countries). United States law, 17 U.S.C. Sec.501 et seq, provides for civil and criminal penalties for copyright infringement.